Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-993-5 | CAS number: 90-43-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
The registered substance is rapidly absorbed via skin and the gastrointestinal tract and widely distributed within the body. OPP is completely metabolised and predominantly excreted via the urine and, to a minor degree, via faeces. There was a low bioaccumulation potential noted in rodents, however, human data indicate that there is no bioaccumulation potential.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Data are available, investigating percutaneous absorption, metabolism and excretion of 14C/13C-2-phenylphenol (14C/13C-OPP) in male volunteers (Bartels, M. J. et al., 1997; Selim, S., 1996 and Bomhard, E. M. et al., 2002). The absorption, distribution, excretion and metabolism of [14C]-OPP was further investigated in young adult male B6C3F1 mice after oral intake. In addition the extent of metabolism was investigated in male and female Fischer 344 rats after oral intake (McNett et al., 1997 and Bomhard, E. M. et al., 2002).
Following 8 h of exposure OPP is rapidly absorbed via human skin with an absorption rate of approximately 43% (Selim, S., 1996 and Bomhard, E. M. et al., 2002). The vast majority of absorbed material is excreted within the first 24 h after application via the renal pathway. The entire absorbed dose is recovered in excreta, thus leaving no potential for systemic or dermal accumulation (Bartels, M. J. et al., 1997; Selim, S., 1996 and Bomhard, E. M. et al., 2002). The major metabolite identified in all urine samples analysed was the sulphate conjugate of OPP. This metabolite accounted for 68.33% of the absorbed dose. Conjugation of OPP with glucuronic acid was less significant, accounting for only 3.46% of the absorbed dose. Hydroxylation of the phenol or phenyl ring, followed by conjugation was shown to be significant, with the glucuronide conjugate of phenyl-hydroquinone (PHQ-Gluc) and 2, 4´ dihydroxy biphenyl-sulfate (2, 4´-DHB-Sulf) representing 14.34% and 12.35% of the absorbed dose, respectively. No sulphate conjugates of PHQ was observed in any of the urine samples analysed, contrary to metabolism of OPP in rat and mouse, in which comparable amounts of both PHQ-conjugates are found, independent from the applied dose. Low levels of free OPP (0.5% of absorbed dose) and the glucuronide conjugate (OPP-Gluc) were observed in the early time intervals. Free OPP was not observed in any of the analysed samples.
In tests with rats and mice after oral dosing (McNett et al., 1997 and Bomhard, E. M. et al., 2002), 97 and 105% of the administered OP (radiolabeld) were recovered after 24 and 48 h, respectively, indicating a fast and complete absorption of OPP via the gastrointestinal tract. Thus, OPP is rapidly bioavailable after oral dosing. Following oral uptake, OPP was shown to be completely metabolised and rapidly eliminated via the renal pathway, predominantly as a sulphate and glucuronide conjugate of OPP. Qualitatively the extent of metabolism was comparable between mice and rats, although quantitative differences in the extent of OPP sulfation and glucuronidation were seen between these species. Only 1% of the administered radioactivity was found in the tissues and carcass of rats, suggesting a low potential for bioaccumulation.
In summary, OPP is rapidly absorbed via skin and the gastrointestinal tract and widely distributed within the body. The bioavailability after oral intake is very high. OPP is completely metabolised and predominantly excreted via the urine and, to a minor degree, via faeces. There was a low bioaccumulation potential noted in rodents, however, human data indicate that there is no bioaccumulation potential.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.